ChemoCentryx, Inc. (CCXI)
| Market Cap | 4.27B |
| Revenue (ttm) | 70.58M |
| Net Income (ttm) | -41.01M |
| Shares Out | 68.92M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $62.02 |
| Previous Close | $63.39 |
| Change ($) | -1.37 |
| Change (%) | -2.16% |
| Day's Open | 63.03 |
| Day's Range | 60.79 - 63.88 |
| Day's Volume | 362,488 |
| 52-Week Range | 32.73 - 65.16 |
MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present a...
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.
MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from...
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present a...
ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), ...
-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing A...
-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -...
ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the Eu...
MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after mark...
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) pa...
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Final Trades: AT&T, Jumia Technologies, Chemocentryx, General Motors
The “Halftime Report” traders give their top picks to watch for the second half.
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Admin...
MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will presen...
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis -- -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total ...
MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after m...
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and D...
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD...
MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. C...
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common...
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In conne...
ChemoCentryx: Avacopan's Attractive Value Proposition
MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline da...
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2019 Results - Earnings Call Transcript
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx: An Intriguing Rare Disease Player In 2020
Positive trial results are always a good thing, but is this newly hyped stock worth it?
ChemoCentryx Brings Hope To Vasculitis Patients, Steroid Therapy Can Play A Smaller Role
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
The company unveiled positive data for the most advanced drug in its pipeline.
Find out how three stocks in very different sectors all posted solid gains.
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks -- -- Significantly reduced gl...
About CCXI
ChemoCentryx, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe h... [Read more...]
| Industry Biotechnology | IPO Date Feb 8, 2012 |
| CEO Thomas Schall | Employees 82 |
| Stock Exchange NASDAQ | Ticker Symbol CCXI |
Financial Performance
In 2019, ChemoCentryx's revenue was $36.13 million, a decrease of -15.74% compared to the previous year's $42.88 million. Losses were -$55.49 million, 46.2% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 80.63, which is an increase of 30.01% from the latest price.